Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization
24 Janeiro 2024 - 10:00AM
Business Wire
New developments in the biopharmaceutical field fuel a need
for highly scalable and flexible solutions
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment and delivery solutions to the pharmaceutical,
biotechnology, and life sciences industries, unveiled today two new
offerings for efficient small batch pharmaceutical manufacturing:
the EZ-fill® Kit and the non-GMP laboratory fill and finish service
at its Technology Excellence Centers (TEC).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240124439132/en/
EZ-fill® Kit by Stevanato Group (Photo:
Business Wire)
In a context where reducing time-to-market is key, Stevanato
Group’s new EZ-fill® Kit offers fast access to a customizable and
versatile solution to pharma and biotech companies needing to
efficiently fill small batches with high-quality injectable
formulations during clinical trials or commercial phases.
The surge the industry has seen in biopharmaceuticals treating
various diseases in several therapeutical areas may signal a
significant growth potential for pharmaceutical companies.
Injectables, comprising more than 60% of the over 21,000 drugs
currently in development, of which 44% are biopharmaceuticals,
require high-performance primary packaging and delivery
technologies for proper storage and administration.
Stevanato Group’s EZ-fill® Kit builds on its existing
ready-to-use platform of pre-sterilized containment solutions –
vials, cartridges, and syringes – allowing customers to effectively
screen different primary packaging in combination with drug
products. The kit will be available as a modular box made up of
glass ready-to-use drug containers and add-on components on
request, shipped by courier. As a result, the platform can bring
enhanced levels of quality and safety to patients across the entire
drug life cycle and improve the rate at which new drugs enter the
market. EZ-fill® Kit will be presented at Pharmapack and is
expected to be available commercially beginning in the second
quarter of 2024.
Additionally, to better support customers, Stevanato Group
has introduced a non-GMP laboratory filling and finishing service
at its Technology Excellence Centers (TEC) in Boston, USA, and
Piombino Dese, Italy. This new service allows customers to assess
and identify the possible effects of the fill-and-finish process on
their product performance as early as the container selection
stage, thus de-risking processes and enhancing development and
commercialization strategy.
“In the race to bring new advanced
biopharmaceutical products to market and to patients, Stevanato
Group is tackling the challenge of supporting customers with
flexible drug containment and filling solutions in a timely
manner," says Fabio Bertacchini, Senior Director EZ-fill® Vials
& Cartridges at Stevanato Group. "Stevanato Group remains
focused on developing new offerings that can help raise
pharmaceutical manufacturing standards. By leveraging the expertise
provided by our global TEC Centers, we aim to support customers'
innovation, helping them face tests and de-risking processes and
making right-the-first-time choices throughout their drug
development journey.”
For more information on Stevanato Group’s EZ-fill® Kit, visit
www.stevanatogroup.com and visit us at Pharmapack booth F46.
* Pharmaprojects 2023 | Pharma R&D Annual Review 2023.
Forward-Looking Statements
This press release may include forward-looking statements. The
words "may,” “potential,” “offers,” “will be,” “can,” “is
expected,” “remains,” “aim,” and similar expressions (or their
negative) identify certain of these forward-looking statements.
These forward-looking statements are statements regarding the
Company's intentions, beliefs or current expectations concerning,
among other things, investments the Company expects to make, the
expansion of manufacturing capacity, the Company’s plans regarding
its presence in the U.S., business strategies, the Company’s
capacity to meet future market demands and support preparedness for
future public health emergencies, and results of operations. The
forward-looking statements in this press release are based on
numerous assumptions regarding the Company’s present and future
business strategies and the environment in which the Company will
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward looking
statements. Many of these risks and uncertainties relate to factors
that are beyond the Company's ability to control or estimate
precisely, such as future market conditions, currency fluctuations,
the behavior of other market participants, the actions of
regulators and other factors such as the Company's ability to
continue to obtain financing to meet its liquidity needs, changes
in the political, social and regulatory framework in which the
Company operates or in economic or technological trends or
conditions. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. Except as required by law, the company
assumes no obligation to update any such forward-looking
statements.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: www.stevanatogroup.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124439132/en/
Media relations: media@stevanatogroup.com Investor
relations: Lisa Miles: lisa.miles@stevanatogroup.com Team
Lewis for Stevanato Group: Cassie Gonzales:
stevanatoUS@teamlewis.com Nicolò Marcon, Arianna Cusolito:
stevanatoita@teamlewis.com
Stevanato (NYSE:STVN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Stevanato (NYSE:STVN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024